KOPIN CORP, 10-Q filed on 11/8/2018
Quarterly Report
v3.10.0.1
Document and Entity Information - shares
9 Months Ended
Sep. 29, 2018
Nov. 05, 2018
Document Documentand Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 29, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Trading Symbol KOPN  
Entity Registrant Name KOPIN CORP  
Entity Central Index Key 0000771266  
Current Fiscal Year End Date --12-29  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   73,135,253
v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 29, 2018
Dec. 30, 2017
Current assets:    
Cash and cash equivalents $ 19,367,048 $ 24,848,227
Marketable debt securities, at fair value 26,835,968 43,907,457
Accounts receivable, net of allowance of $468,000 in 2018 and $149,000 in 2017 2,628,139 3,955,123
Contract with Customer, Asset, Net 1,935,262 704,863
Inventory 4,953,908 5,080,797
Prepaid taxes 133,445 264,352
Prepaid expenses and other current assets 1,044,374 978,677
Total current assets 56,898,144 79,739,496
Property, plant and equipment, net 5,075,602 5,077,043
Goodwill 1,761,136 1,780,247
Finite-Lived Intangible Assets, Net 220,909 883,636
Other assets 2,096,578 3,842,068
Financial Instruments, Owned, at Fair Value 5,572,816 0
Total assets 71,625,185 91,322,490
Current liabilities:    
Accounts payable 4,229,387 4,918,605
Accrued payroll and expenses 2,169,492 1,636,512
Accrued warranty 587,000 649,000
Contract with Customer, Liability 428,642 896,479
Other accrued liabilities 2,095,098 2,066,025
Income tax payable 1,573 1,416,892
Deferred tax liabilities 547,266 520,000
Total current liabilities 10,058,458 12,103,513
Deferred Revenue, Noncurrent 154,769 374,171
Asset retirement obligations 260,660 269,877
Liabilities, Other than Long-term Debt, Noncurrent 1,925,911 1,195,082
Stockholders’ equity:    
Preferred stock, par value $.01 per share: authorized, 3,000 shares; none issued 0 0
Common stock, par value $.01 per share: authorized, 120,000,000 shares; issued 81,124,758 shares in 2018 and 80,201,313 shares in 2017; outstanding 73,135,253 shares in 2018 and 73,058,783 shares in 2017 776,485 775,720
Additional paid-in capital 334,985,791 331,119,340
Treasury stock (4,513,256 shares in 2018 and 2017, at cost) (17,238,669) (17,238,669)
Accumulated other comprehensive income 3,036,681 3,564,779
Accumulated deficit (261,631,136) (240,121,901)
Total Kopin Corporation stockholders’ equity 59,929,152 78,099,269
Noncontrolling interest (703,765) (719,422)
Total stockholders’ equity 59,225,387 77,379,847
Total liabilities and stockholders’ equity $ 71,625,185 $ 91,322,490
v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Sep. 29, 2018
Dec. 30, 2017
Statement of Financial Position [Abstract]    
Accounts receivable, allowance $ 468,000 $ 149,000
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, authorized 3,000 3,000
Preferred stock, issued 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, authorized 120,000,000 120,000,000
Common stock, issued 81,124,758 80,201,313
Common stock, outstanding 73,135,253 73,058,783
Treasury stock, shares 4,513,256 4,513,256
v3.10.0.1
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 29, 2018
Sep. 30, 2017
Sep. 29, 2018
Sep. 30, 2017
Revenues:        
Research and development revenues $ 1,482,711 $ 549,765 $ 3,563,341 $ 1,942,819
Revenues 5,126,330 6,139,167 16,723,848 16,444,764
Expenses:        
Research and development 4,599,266 5,253,860 13,577,075 14,213,950
Selling, general and administration 7,166,137 5,344,999 21,011,050 16,186,946
Total expenses 15,425,203 14,743,743 45,807,866 41,780,363
Loss from operations (10,298,873) (8,604,576) (29,084,018) (25,335,599)
Other income and expense:        
Interest income 160,875 191,613 486,239 611,532
Other income 241,466 (109,546) 1,360,822 215,883
Foreign currency transaction (losses) gains (227,447) 224,370 (254,615) (410,373)
Gain on investments 0 0 2,849,816 274,000
Total other income and expense 174,894 306,437 4,442,262 691,042
Loss before (provision) benefit for income taxes and net loss (income) attributable to noncontrolling interest (10,123,979) (8,298,139) (24,641,756) (24,644,557)
Tax (provision) benefit 316,000 (4,500) 115,000 1,141,500
Net loss (9,807,979) (8,302,639) (24,526,756) (23,503,057)
Net loss (income) attributable to noncontrolling interest 16,596 55,217 (41,862) 65,223
Net loss attributable to Kopin Corporation $ (9,791,383) $ (8,247,422) $ (24,568,618) $ (23,437,834)
Net (loss) income per share        
Basic and diluted (usd per share) $ (0.13) $ (0.11) $ (0.34) $ (0.34)
Weighted average number of common shares        
Basic and diluted (in shares) 73,135,253 72,187,688 73,102,979 69,117,640
Product [Member]        
Revenues:        
Research and development revenues $ 1,482,711   $ 3,563,341  
Revenues 3,643,619 $ 5,589,402 13,160,507 $ 14,501,945
Other income and expense:        
Cost of Goods and Services Sold 3,659,800 $ 4,144,884 11,219,741 $ 11,379,467
Net loss attributable to Kopin Corporation $ (9,791,383)   $ (24,568,618)  
v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
3 Months Ended 9 Months Ended
Sep. 29, 2018
Sep. 30, 2017
Sep. 29, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
Net loss $ (9,807,979) $ (8,302,639) $ (24,526,756) $ (23,503,057)
Other comprehensive (loss) income, net of tax:        
Foreign currency translation adjustments 68,890 (272,618) (266,807) 658,443
Unrealized holding losses on marketable securities (103,212) (29,584) (313,348) 108,196
Reclassification of holding losses in net loss 27,620 (1,238) 25,852 (5,138)
Other comprehensive (loss) income, net of tax (6,702) (303,440) (554,303) 761,501
Comprehensive loss (9,814,681) (8,606,079) (25,081,059) (22,741,556)
Comprehensive loss attributable to the noncontrolling interest 13,788 63,306 (15,657) 79,660
Comprehensive loss attributable to controlling interest $ (9,800,893) $ (8,542,773) $ (25,096,716) $ (22,661,896)
v3.10.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Other Comprehensive Income
Accumulated Deficit
Total Kopin Corporation Stockholders’ Equity
Noncontrolling Interest
Beginning balance at Dec. 31, 2016 $ 74,219,643 $ 766,409 $ 328,524,644 $ (42,741,551) $ 1,570,971 $ (214,042,787) $ 74,077,686 $ 141,957
Beginning Balance (in shares) at Dec. 31, 2016   76,640,943            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation 2,484,757   2,484,757       2,484,757  
Vesting of restricted stock (shares)   60,000            
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures   $ 600 (600)          
Other comprehensive loss 761,501       775,938   775,938 (14,437)
Stock Issued During Period, Value, Treasury Stock Reissued (24,664,250)     (25,502,882)   (838,632) (24,664,250)  
Net loss (23,503,057)         (23,437,834) (23,437,834) (65,223)
Ending balance at Sep. 30, 2017 78,627,094 $ 767,009 331,008,801 (17,238,669) 2,346,909 (238,319,253) 78,564,797 62,297
Ending Balance (in shares) at Sep. 30, 2017   76,700,943            
Beginning balance at Dec. 30, 2017 77,379,847 $ 775,720 331,119,340 (17,238,669) 3,564,779 (240,121,901) 78,099,269 (719,422)
Beginning Balance (in shares) at Dec. 30, 2017   77,572,038            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation 3,878,619   3,878,619       3,878,619  
Vesting of restricted stock (shares)   80,000            
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures   $ 800 (800)          
Stock Repurchased During Period, Shares   (3,530)            
Payments for Repurchase of Common Stock (11,403) $ (35) (11,368)       (11,403)  
Other comprehensive loss (554,303)       (528,098)   (528,098) (26,205)
Gain (Loss) on Sale of Treasury Stock 3,059,383           3,059,383  
Net loss (24,526,756)         (24,568,618) (24,568,618) 41,862
Ending balance at Sep. 29, 2018 $ 59,225,387 $ 776,485 $ 334,985,791 $ (17,238,669) $ 3,036,681 $ (261,631,136) $ 59,929,152 $ (703,765)
Ending Balance (in shares) at Sep. 29, 2018   77,648,508            
v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended
Sep. 29, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net loss $ (24,526,756) $ (23,503,057)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 1,688,715 1,878,363
Stock-based compensation 3,878,619 2,990,157
Foreign currency losses 269,239 400,542
Provision for Doubtful Accounts (333,889) 0
Unrealized gain on investments (2,849,816) (274,000)
Deferred income taxes 70,803 (1,170,017)
Other non-cash items 519,027 781,927
Changes in assets and liabilities, net of acquired assets and liabilities:    
Accounts receivable 1,504,218 71,400
Increase (Decrease) in Cost in Excess of Billing on Uncompleted Contract 1,619,875 0
Inventory (1,551,859) (2,519,197)
Prepaid expenses and other current assets 144,421 13,345
Accounts payable and accrued expenses (664,524) 1,743,215
Billings in excess of revenue earned 49,174 (253,480)
Net cash used in operating activities (20,182,753) (19,840,802)
Cash flows provided by investing activities:    
Other assets (7,616) (79,916)
Capital expenditures (959,488) (1,341,744)
Proceeds from sale of marketable debt securities 21,858,785 33,395,422
Payments to Acquire Equity Method Investments (1,000,000) 0
Purchase of marketable debt securities (4,910,630) (22,974,668)
Cash paid for acquisition, net of cash acquired 0 (3,690,047)
Net cash provided by investing activities 14,981,051 5,309,047
Cash flows (used in) provided by financing activities:    
Proceeds from Sale of Treasury Stock 0 24,664,250
Payments Related to Tax Withholding for Share-based Compensation 11,403 0
Net Cash Provided by (Used in) Financing Activities (11,403) 24,664,250
Effect of exchange rate changes on cash (268,074) (72,436)
Net (decrease) increase in cash and cash equivalents (5,481,179) 10,060,059
Cash and equivalents:    
Beginning of period 24,848,227 25,882,554
End of period 19,367,048  
Supplemental disclosure of cash flow information:    
Income taxes paid $ 1,300,000 $ 0
v3.10.0.1
BASIS OF PRESENTATION
9 Months Ended
Sep. 29, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
BASIS OF PRESENTATION
The condensed consolidated financial statements of Kopin Corporation as of September 29, 2018 and for the three and nine month periods ended September 29, 2018 and September 30, 2017 are unaudited and include all adjustments that in the opinion of management, are necessary to present fairly the results of operations for the periods then ended. These condensed consolidated financial statements should be read in conjunction with the Company’s financial statements and notes thereto, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2017. The results of the Company's operations for any interim period are not necessarily indicative of the results of the Company's operations for any other interim period or for a full fiscal year. The Company reclassified certain prior period amounts to conform to the current period presentation. As used in this report, the terms "we", "us", "our", "Kopin" and the "Company" mean Kopin Corporation and its subsidiaries, unless the context indicates another meaning.
v3.10.0.1
ACCOUNTING STANDARDS (Notes)
9 Months Ended
Sep. 29, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Abstract]  
Basis of Presentation and Significant Accounting Policies [Text Block]
2.
ACCOUNTING STANDARDS
Recently Issued Accounting Pronouncements
Leases    
In February 2016, the FASB issued ASU No. 2016-02 (Topic 842) Leases, which requires lessees to recognize a right-of-use asset and lease liability for most lease arrangements. The Company will adopt the standard effective at the beginning of fiscal year 2019. Interpretations are on-going and could have a material impact on the Company's implementation. Currently, the Company expects that the adoption of the ASU 2016-02 (Topic 842) Leases will have a material impact on its consolidated balance sheet due to the recognition of right-of-use assets and lease liabilities principally for certain leases currently accounted for as operating leases, but the Company does not expect it to have a material impact on our results of operations or liquidity.
Recently Adopted Accounting Pronouncements
Recognition and Measurement of Financial Assets and Liabilities
The Company adopted ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities and the related amendments on December 31, 2017 (the first day of the Company's fiscal year 2018). This standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. As a result, these investments will be revalued upon occurrence of an observable price change for similar investments and for impairments.
Revenue from Contracts with Customers
The Company adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) effective December 31, 2017 and applied the modified retrospective method. The Company recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company expects the impact of the adoption of the new standard to be material to the Company's results of operations on an ongoing basis.
Significant Accounting Policies Update
The Company's significant accounting policies are detailed in "Note 1: Summary of Significant Accounting Policies" of our Annual Report on Form 10-K for the fiscal year ended December 30, 2017. Significant changes to the Company's accounting policies as a result of adopting Topic 606 are discussed below.
Revenue Recognition
Substantially all of our revenues are either derived from the sales of components for use in military applications or our wearable technology components that can be integrated to create industrial and consumer headset systems. We also have development contracts for the design, manufacture and modification of products for the U.S. government or a prime contractor for the U.S. government (“U.S. government”) or for a customer that sells into the industrial or consumer markets. The Company's contracts with the U.S. government are typically subject to the Federal Acquisition Regulations (“FAR”) and are priced based on estimated or actual costs of producing goods. The FAR provides guidance on the types of costs that are allowable in establishing prices for goods provided under U.S. government contracts. The pricing for non-U.S. government contracts is based on the specific negotiations with each customer.
Our fixed-price contracts with the U.S. government may result in revenue recognized in excess of amounts actually billed. We disclose the in excess of revenues over amounts actually billed as Contract assets and unbilled receivables on the balance sheet. Amounts billed and due from our customers are classified as Accounts receivable on the balance sheets. In some instances, the U.S. government retains a small portion of the contract price until completion of the contract. The portion of the payments retained until final contract settlement is not considered a significant financing component because the intent is to protect the customer. For contracts with the U.S. government, we typically receive interim payments either as work progresses, we achieve certain milestones or based on a schedule in the contract. We recognize a liability for these advance payments in excess of revenue recognized and present it as Contract liabilities and billings in excess of revenue earned on the balance sheets. The advanced payment typically is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. For industrial and consumer purchase orders, we typically receive payments within 30 to 60 days of shipments of the product, although for some purchase orders, we may require an advanced payment prior to shipment of the product.
To determine the proper revenue recognition method for complex contracts with the same customer, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment and the decision to combine a group of contracts or separate the combined or single contract into multiple performance obligations could change the amount of revenue and profit recorded in a given period. For most of our development contracts and contracts with the U.S government, the customer contracts with us to provide a significant service of integrating a set of components into a single unit. Hence, the entire contract is accounted for as one performance obligation. Less common, however, we may promise to provide distinct goods or services within a contract in which case we separate the contract into more than one performance obligation. If a contract is separated into more than one performance obligation, we allocate the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. In cases where we sell standard products, the observable standalone sales are used to determine the standalone selling price.
The Company recognizes revenue from a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For certain contracts that meet the foregoing requirements, primarily international direct commercial and military sale contracts, we recognize revenue once we have obtained all regulatory approvals.
Commencing in 2018 for certain contracts with the U.S. government, the Company recognizes revenue over time as we perform because of continuous transfer of control to the customer and the lack of an alternative use for the product. The continuous transfer of control to the customer is supported by liability clauses in the contract that allow the U.S. government to unilaterally terminate the contract for convenience, pay us for costs incurred plus a reasonable profit and take control of any work in process. For contracts with commercial customers, while the contract may have a similar liability clause, our products historically have an alternative use and thus, revenue is recognized at a point in time.
In situations where control transfers over time, revenue is recognized based on the extent of progress towards completion of the performance obligation. We generally use the cost-to-cost approach to measure the extent of progress towards completion of the performance obligation for our contracts because we believe it best depicts the transfer of assets to the customer, which occurs as we incur costs on our contracts. Under the cost-to-cost measure approach, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. Revenues are recorded proportionally as costs are incurred.
Accounting for design, development and production contracts requires judgment relative to assessing risks, estimating contract revenues and costs, and making assumptions for schedule and technical issues. Due to the size and nature of the work required to be performed on many of our contracts, the estimation of total revenue and cost at completion is complicated and subject to many variables. Contract costs include material, labor and subcontracting costs, as well as an allocation of indirect costs. We have to make assumptions regarding the number of labor hours required to complete a task, the complexity of the work to be performed, the availability and cost of materials, and performance by our subcontractors. For contract change orders, claims or similar items, we apply judgment in estimating the amounts and assessing the potential for realization. These amounts are only included in contract value when they can be reliably estimated and realization is considered probable. If our estimate of total contract costs or our determination of whether the customer agrees that a milestone is achieved is incorrect, our revenue could be overstated or understated and the profits or loss reported could be wrong.
For our commercial customers, the Company's revenue is recognized when obligations under the terms of a contract with our customer is satisfied; generally this occurs with the transfer of control of the Company's products or services. Revenue is recorded as the amount of consideration we expect to receive in exchange for transferring goods or providing services. Provisions for product returns and allowances are recorded in the same period as the related revenues. We analyze historical returns, current economic trends and changes in customer demand and acceptance of product when evaluating the adequacy of sales returns and other allowances. Certain product sales are made to distributors under agreements allowing for a limited right of return on unsold products. Sales to distributors are primarily made for sales to the distributors' customers and not for stocking of inventory. We delay revenue recognition for our estimate of distributor claims of right of return on unsold products based upon our historical experience with our products and specific analysis of amounts subject to return based upon discussions with our distributors or their customers. Sales, value add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue.
The rights and benefits to the Company's intellectual property are conveyed to certain customers through technology license agreements. These agreements may include other performance obligations including the sale of product to the customer. When the license is distinct from other obligations in the agreement, the Company treats the license and other performance obligations as separate performance obligations. Accordingly, the license is recognized at a point in time or over time based on the standalone selling price. The sale of materials is recognized at a point in time, which occurs with the transfer of control of the Company's products or services. In certain instances, the Company is entitled to sales-based royalties under license agreements. These sales-based royalties are recognized when they are earned.
The cumulative effect of the changes made to the Company's consolidated December 31, 2017 balance sheet for the adoption of ASU 2014-09, Revenue from Contracts with Customers (Topic 606) was as follows:
Balance Sheet
Balance at December 30, 2017
 
Adjustments due to Topic 606
 
Balance at December 31, 2017
Assets
 
 
 
 
 
Contract assets and unbilled receivables
$
704,863

 
$
2,850,274

 
$
3,555,137

Inventory
5,080,797

 
(1,082,629
)
 
3,998,168

Other assets
3,842,068

 
400,000

 
4,242,068

 
 
 
 
 
 
Liabilities
 
 
 
 
 
Contract liabilities and billings in excess of revenue earned
1,555,883

 
(891,737
)
 
664,146

 
 
 
 
 
 
Stockholders’ equity
 
 
 
 
 
Accumulated Deficit
$
(240,121,901
)
 
$
3,059,382

 
$
(237,062,519
)
In accordance with the new revenue standard requirements, the impact of adoption on the Company's condensed consolidated statement of operations was as follows:
 
Three Months Ended September 29, 2018
Statement of Operations
As Reported
 
Balances Without Adoption of
Topic 606
 
Effect of Change Higher/(Lower)
Net product revenues
$
3,643,619

 
$
3,878,651

 
$
(235,032
)
Research and development revenues
1,482,711

 
1,569,255

 
(86,544
)
Cost of product revenues
3,659,800

 
3,497,549

 
162,251

Net loss attributable to Kopin Corporation
$
(9,791,383
)
 
$
(9,307,556
)
 
$
(483,827
)
 
 
 
 
 
 
 
Nine Months Ended September 29, 2018
Statement of Operations
As Reported
 
Balances Without Adoption of
Topic 606
 
Effect of Change Higher/(Lower)
Net product revenues
$
13,160,507

 
$
14,867,927

 
$
(1,707,420
)
Research and development revenues
3,563,341

 
3,822,973

 
(259,632
)
Cost of product revenues
11,219,741

 
11,997,670

 
(777,929
)
Net loss attributable to Kopin Corporation
$
(24,568,618
)
 
$
(23,379,495
)
 
$
(1,189,123
)

See Note 13. Segments and Disaggregation of Revenue for additional information regarding the disaggregation of the Company's revenue by major source and the Company's updated accounting policy for revenue recognition.
Contract Assets
Contract assets include unbilled amounts typically resulting from sales under contracts when the cost-to-cost method of revenue recognition is utilized and revenue recognized from customer arrangements, including licensing, exceeds the amount billed to the customer, and right to payment is not just subject to the passage of time. Amounts may not exceed their net realizable value. Contract assets are generally classified as current. The Company classifies the noncurrent portion of contract assets under other assets in its condensed consolidated balance sheets.
Contract Liabilities
Contract liabilities consist of advance payments and billings in excess of cost incurred and deferred revenue.
Performance Obligations
The Company's performance obligations that were satisfied at a point in time accounted for 63% and 91% of the Company's total revenue for the three months ended September 29, 2018 and September 30, 2017, respectively, and 63% and 88% of the Company's total revenue for the nine months ended September 29, 2018 and September 30, 2017, respectively. The Company's performance obligations that were satisfied over time accounted for 37% and 9% of the Company's total revenue for the three months ended September 29, 2018 and September 30, 2017, respectively, and 37% and 12% of the Company's total revenue for the nine months ended September 29, 2018 and September 30, 2017, respectively.
Remaining performance obligations represent the transaction price of orders for which work has not been performed and excludes unexercised contract options and potential orders under ordering-type contracts (e.g., indefinite-delivery, indefinite-quantity ("IDIQ")). As of September 29, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was $8.8 million. The Company expects to recognize revenue on the remaining performance obligations of $8.8 million over the next 12 months.
v3.10.0.1
CASH AND EQUIVALENTS AND MARKETABLE SECURITIES
9 Months Ended
Sep. 29, 2018
Cash and Equivalents and Marketable Securities Disclosure [Abstract]  
CASH AND EQUIVALENTS AND MARKETABLE SECURITIES
CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES
The Company considers all highly liquid, short-term debt instruments with original maturities of three months or less to be cash equivalents.
Marketable debt securities consist primarily of commercial paper, medium-term corporate notes, and U.S. government and agency backed securities. The Company classifies these marketable debt securities as available-for-sale at fair value in “Marketable debt securities, at fair value.” The Company records the amortization of premium and accretion of discounts on marketable debt securities in the results of operations.
The Company uses the specific identification method as a basis for determining cost and calculating realized gains and losses with respect to marketable debt securities. The gross gains and losses realized related to sales and maturities of marketable debt securities were not material during the three and nine months ended September 29, 2018 and the fiscal year ended December 30, 2017.
Investments in available-for-sale marketable debt securities were as follows at September 29, 2018 and December 30, 2017:
 
Amortized Cost

Unrealized (Losses) Gains

Fair Value
 
2018

2017

2018

2017

2018

2017
U.S. government and agency backed securities
$
16,070,511


$
35,014,593


$
(414,404
)

$
(288,782
)

$
15,656,107


$
34,725,811

Corporate debt
11,178,825

 
8,988,608

 
1,036

 
(7,702
)
 
11,179,861

 
8,980,906

Certificates of deposit


201,000




(260
)



200,740

Total
$
27,249,336

 
$
44,204,201

 
$
(413,368
)
 
$
(296,744
)
 
$
26,835,968

 
$
43,907,457


The contractual maturity of the Company’s marketable debt securities was as follows at September 29, 2018:
 
Less than
One year
 
One to
Five years
 
Greater than
Five years
 
Total
U.S. government and agency backed securities
$
6,223,207

 
$
9,432,900

 
$

 
$
15,656,107

Corporate debt
3,213,495

 
7,966,366

 

 
11,179,861

Total
$
9,436,702

 
$
17,399,266

 
$

 
$
26,835,968


The Company conducts a review of its marketable debt securities on a quarterly basis for the presence of other-than-temporary impairment ("OTTI"). The Company assesses whether OTTI is present when the fair value of a debt security is less than its amortized cost basis at the balance sheets date. Under these circumstances OTTI is considered to have occurred if (1) the Company intends to sell the security before recovery of its amortized cost basis; (2) it is “more likely than not” the Company will be required to sell the security before recovery of its amortized cost basis; or (3) the present value of expected cash flows is not sufficient to recover the entire amortized cost basis.
The Company further estimates the amount of OTTI resulting from a decline in the creditworthiness of the issuer (credit-related OTTI) and the amount of non credit-related OTTI. Non-credit-related OTTI can be caused by such factors as market illiquidity. Credit-related OTTI is recognized in earnings while non-credit-related OTTI on securities not expected to be sold is recognized in other comprehensive income (loss). The Company did not record OTTI for the three and nine months ended September 29, 2018 and September 30, 2017.
v3.10.0.1
FAIR VALUE MEASUREMENTS
9 Months Ended
Sep. 29, 2018
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS
Financial instruments are categorized as Level 1, Level 2 or Level 3 based upon the method by which their fair value is computed. An investment is categorized as Level 1 when its fair value is based on unadjusted quoted prices in active markets for identical assets that the Company has the ability to access at the measurement date. An investment is categorized as Level 2 if its fair market value is based on quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, based on observable inputs such as interest rates, yield curves, or derived from or corroborated by observable market data by correlation or other means. An investment is categorized as Level 3 if its fair value is based on assumptions developed by the Company about what a market participant would use in pricing the assets.
The following table details the fair value measurements of the Company’s financial assets:
 
 
 
Fair Value Measurement September 29, 2018 Using:
 
Total
 
Level 1
 
Level 2
 
Level 3
Cash and Cash Equivalents
$
19,367,048

 
$
19,367,048

 
$

 
$

U.S. Government Securities
15,656,107

 
998,100

 
14,658,007

 

Corporate Debt
11,179,861

 

 
11,179,861

 

GCS Holdings
307,644

 
307,644

 

 

Equity Investments
5,572,816

 

 

 
5,572,816

 
$
52,083,476

 
$
20,672,792

 
$
25,837,868

 
$
5,572,816

 
 
 
 
 
 
 
 
 
 
 
Fair Value Measurement December 30, 2017 Using:
 
Total
 
Level 1
 
Level 2
 
Level 3
Cash and Cash Equivalents
$
24,848,227

 
$
24,848,227

 
$

 
$

U.S. Government Securities
34,725,811

 
6,927,323

 
27,798,488

 

Corporate Debt
8,980,906

 

 
8,980,906

 

Certificates of Deposit
200,740

 

 
200,740

 

GCS Holdings
478,546

 
478,546

 

 

Warrant
2,000,000

 

 

 
2,000,000

 
$
71,234,230

 
$
32,254,096

 
$
36,980,134

 
$
2,000,000

Transfers between levels of the fair value hierarchy are reported at the beginning of the reporting period in which they occur. Changes in Level 3 investments were as follows:
 
December 30, 2017
 
Net unrealized losses
 
Purchases, issuances and settlements
 
Transfers in and or out of Level 3
 
September 29, 2018
Equity Investments
$

 
$
(277,000
)
 
$
5,849,816

 
$

 
$
5,572,816

Warrant
2,000,000

 
(50,184
)
 
(1,949,816
)
 

 

 
$
2,000,000

 
$
(327,184
)
 
$
3,900,000

 
$

 
$
5,572,816


The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of their short-term nature. If accrued liabilities were carried at fair value, these would be classified as Level 2 in the fair value hierarchy.
Marketable Debt Securities
The corporate debt consists of floating rate notes with a maturity that is over multiple years but has interest rates that are reset every three months based on the then-current three-month London Interbank Offering Rate ("three-month Libor"). The Company validates the fair market values of the financial instruments above by using discounted cash flow models, obtaining independent pricing of the securities or through the use of a model that incorporates the three-month Libor, the credit default swap rate of the issuer and the bid and ask price spread of the same or similar investments which are traded on several markets.
Warrant
The Company had a warrant to acquire up to 15% of the next round of equity offered by a customer as part of the licensing of technology to the customer. The Company exercised the warrant in April 2018.
Equity Investments
The Company adopted ASU No. 2016-01 and the related amendments on December 31, 2017 (the first day of the Company's fiscal year 2018). This standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. As a result, these investments will be revalued upon occurrence of an observable price change for similar investments and for impairments. See Note 8. Equity Investments for additional information regarding the Company's equity investments.
v3.10.0.1
INVENTORY
9 Months Ended
Sep. 29, 2018
Inventory Disclosure [Abstract]  
INVENTORY
INVENTORY
Inventories are stated at standard cost adjusted to approximate the lower of cost (first-in, first-out method) or net realizable value and consist of the following at September 29, 2018 and December 30, 2017:
 
September 29, 2018
 
December 30, 2017
Raw materials
$
2,438,941

 
$
2,070,153

Work-in-process
1,263,099

 
1,829,805

Finished goods
1,251,868

 
1,180,839

 
$
4,953,908

 
$
5,080,797

v3.10.0.1
NET LOSS PER SHARE
9 Months Ended
Sep. 29, 2018
Earnings Per Share [Abstract]  
NET LOSS PER SHARE
NET LOSS PER SHARE
Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period less any unvested restricted shares. Diluted net loss per share is calculated using weighted-average shares outstanding and contingently issuable shares, less weighted-average shares reacquired during the period. The net outstanding shares are adjusted for the dilutive effect of shares issuable upon the assumed conversion of the Company’s common stock equivalents, which consist of unvested restricted stock.
The following were not included in weighted-average common shares outstanding-diluted because they are anti-dilutive or performance conditions have not been met at the end of the period:
 
Three Months Ended
 
Nine Months Ended
 
September 29, 2018
 
September 30, 2017
 
September 29, 2018
 
September 30, 2017
Non-vested restricted common stock
3,476,249

 
2,968,874

 
3,476,249

 
2,968,874

v3.10.0.1
STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION
9 Months Ended
Sep. 29, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION
STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION
Non-Vested Restricted Common Stock
The fair value of non-vested restricted common stock awards is generally the market value of the Company’s common stock on the date of grant. The non-vested restricted common stock awards require the employee to fulfill certain obligations, including remaining employed by the Company for one, two or four years (the vesting period) and in certain cases also require meeting either performance criteria or the Company’s stock achieving a certain price. For non-vested restricted common stock awards that solely require the recipient to remain employed with the Company, the stock compensation expense is amortized over the anticipated service period. For non-vested restricted common stock awards that require the achievement of performance criteria, the Company reviews the probability of achieving the performance goals on a periodic basis. If the Company determines that it is probable that the performance criteria will be achieved, the amount of compensation cost derived for the performance goal is amortized over the anticipated service period. If the performance criteria are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed.
Restricted stock activity was as follows:
 
Shares
 
Weighted
Average
Grant
Fair
Value
Balance, December 30, 2017
2,629,274

 
$
3.31

Granted
1,549,000

 
2.25

Forfeited
(622,025
)
 
4.13

Vested
(80,000
)
 
3.64

Balance, September 29, 2018
3,476,249

 
$
2.69


On December 31, 2017, the Company amended the employment agreement with our CEO, Dr. John Fan, to expire on December 31, 2020 and as part of the amendment issued restricted stock grants. Of the restricted stock grants issued to Dr. Fan, 640,000 shares will vest upon the first 20 consecutive trading day period following the grant date during which the Company's common stock trades at a price equal to or greater than $5.25150,000 shares will vest at the end of the first 20 consecutive trading day period following the grant date during which the Company’s common stock trades at a price per share equal to or greater than $6.00, and 150,000 shares will vest at the end of the first 20 consecutive trading day period following the grant date during which the Company’s common stock trades at a price per share equal to or greater than $7.00. All of the grants are subject to certain acceleration events and expire on December 31, 2020. The total fair value of these awards on December 31, 2017 was $1.7 million. The value of restricted stock grants that vest based on market conditions is computed on the date of grant using the Monte Carlo model with the following assumptions:
 
For the period ended September 29, 2018
Performance price target
$
5.25

 
$
6.00

 
$
7.00

Expected volatility
48.3
%
 
48.3
%
 
48.3
%
Interest rate
1.97
%
 
1.97
%
 
1.97
%
Expected life (years)
3

 
3

 
3

Dividend yield
%
 
%
 
%

Stock-Based Compensation
The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the three and nine months ended September 29, 2018 and September 30, 2017 (no tax benefits were recognized):
 
Three Months Ended
 
Nine Months Ended
 
September 29, 2018
 
September 30, 2017
 
September 29, 2018
 
September 30, 2017
Cost of product revenues
$
52,368

 
$
142,604

 
$
318,519

 
$
405,778

Research and development
159,436

 
203,288

 
627,519

 
616,500

Selling, general and administrative
979,026

 
676,137

 
2,932,581

 
1,967,879

Total
$
1,190,830

 
$
1,022,029

 
$
3,878,619

 
$
2,990,157

Unrecognized compensation expense for non-vested restricted common stock as of September 29, 2018 totaled $4.6 million and is expected to be recognized over a weighted average period of approximately two years.
v3.10.0.1
EQUITY INVESTMENTS
9 Months Ended
Sep. 29, 2018
Equity Method Investments and Joint Ventures [Abstract]  
Equity Investments
The Company acquired an equity interest in a company in the first quarter of 2018. The Company made a $1.0 million capital contribution during the three months ended March 31, 2018. The Company also contributed certain intellectual property. As of September 29, 2018, the Company owns 12.5% interest in this investment and the carrying value of the Company's investment is $3.9 million. The Company recorded a $0.3 million unrealized loss in the nine months ended September 29, 2018 in this equity investment due to a fluctuation in the foreign exchange rate. The fair value of this equity investment is approximately $3.6 million.
The Company acquired an interest in an equity investment by exercising a warrant to acquire up to 15% of the next round of equity offered by a customer as part of the licensing of technology to the customer. The Company used the customer's capital structure, pricing of the shares being offered and 15% from the customer's qualified financing round in determining the value of its equity investment. The Company recorded an unrealized loss of less than $0.1 million in the nine months ended September 29, 2018 in this equity investment due to a change in the Company's estimate of the value of the equity investment based on the observable transaction price at the exercise date of the warrant. The fair value of this equity investment is approximately $1.9 million.
The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. As a result, these investments will be revalued upon occurrence of an observable price change for similar investments and for impairments. The Company did not have an observable price change for similar investments of its equity investments and recorded no impairments on its equity investments during the three months ended September 29, 2018.
v3.10.0.1
(Notes)
9 Months Ended
Sep. 29, 2018
Product Warranties Disclosures [Abstract]  
ACCRUED WARRANTY
ACCRUED WARRANTY
The Company typically warrants its products against defect for 12 to 18 months, however, for certain products a customer may purchase an extended warranty. A provision for estimated future costs and estimated returns for credit relating to such warranty is recorded in the period when product is shipped and revenue recognized, and is updated as additional information becomes available. The Company’s estimate of future costs to satisfy warranty obligations is based primarily on historical warranty expense experienced and a provision for potential future product failures. Changes in the accrued warranty for the nine months ended September 29, 2018 were as follows:
Balance, December 30, 2017
$
649,000

Additions
120,000

Claims
(182,000
)
Balance, September 29, 2018
$
587,000


Extended Warranties
Deferred revenue represents the purchase of extended warranties by the Company's customers. The Company recognizes revenue from an extended warranty on the straight-line method over the life of the extended warranty, which is typically 12 to 15 months beyond the standard 12 to 18 month warranty. The Company classifies the current portion of deferred revenue under Other accrued liabilities in its condensed consolidated balance sheets. The Company currently has $0.5 million of deferred revenue related to extended warranties.
v3.10.0.1
INCOME TAXES
9 Months Ended
Sep. 29, 2018
Income Tax Disclosure [Abstract]  
INCOME TAXES
INCOME TAXES
The Company recorded a tax benefit of approximately $0.3 million and $0.1 million for the three months and nine months ended September 29, 2018, respectively. The tax benefit for the three months and nine months ended September 29, 2018 was due to a change in estimate related to deferred tax liabilities for the Company's withholding tax on future repatriated earnings from the Company's Korean subsidiary. The Company’s tax benefit of approximately $1.1 million for the nine months ended September 30, 2017, represents the net benefit of $0.1 million for foreign income taxes including loss carryback to 2016, uncertain tax positions and a benefit for the net reduction in estimated foreign withholding. In addition, as a result of the acquisition of NVIS, Inc. in the first quarter of 2017, we recognized $1.0 million of deferred tax liabilities, which provided evidence of recoverability of our net deferred tax assets that previously carried a full valuation allowance. We reduced the valuation allowance on our net deferred tax assets in the amount of $1.0 million and such reduction was recognized as a benefit for income taxes for the nine months ended September 30, 2017. As of September 29, 2018, the Company has available for tax purposes U.S. federal NOLs of approximately $184.0 million expiring 2022 through 2037. The Company has recognized a full valuation allowance on its domestic and certain foreign net deferred tax assets due to the uncertainty of realization of such assets.
Ownership changes, as defined by the Internal Revenue Code, may substantially limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income. The ownership change of NVIS, Inc. in 2017 did not result in an annual net operating loss limitation as the acquired entity was an S Corporation and did not have loss carryforwards. Subsequent ownership changes could affect the limitation in future years. Such annual limitations could result in the expiration of net operating loss and tax credit carryforwards before utilization.
The tax years 2001 through 2016 remain open to examination by major taxing jurisdictions where the Company is subject to United States federal tax. These periods have carryforward attributes generated in years past that may still be adjusted upon examination by the Internal Revenue Service or state tax authorities if they have or will be used in a future period. State statutes are generally shorter with shorter carryforward periods. The Company is currently not under examination by the Internal Revenue Service and is currently under examination by Massachusetts for the 2013 tax year. The Company recognizes both accrued interest and penalties related to its uncertain tax positions related to intercompany loan interest and potential transfer pricing exposure related to its Korean subsidiary.
The Company is in the process of dissolving and repatriating the unremitted earnings of its Korean subsidiary. As such, it accrues U.S. tax for the possible future repatriation of these unremitted foreign earnings. If the Company were to repatriate these earnings, it expects to have foreign withholding at a rate of 16.5% and does not expect any taxes to be paid in the U.S. when repatriated as it currently is expected to be a return of capital.
v3.10.0.1
GOODWILL AND INTANGIBLE ASSETS
9 Months Ended
Sep. 29, 2018
Goodwill, Translation and Purchase Accounting Adjustments [Abstract]  
Goodwill and Intangible Assets
A rollforward of the Company's goodwill by segment is as follows:
 
Kopin
 
Industrial
 
Total
Balance, December 30, 2017
$
891,683

 
$
888,564

 
$
1,780,247

Change due to exchange rate fluctuations
(19,111
)
 

 
(19,111
)
Balance, September 29, 2018
$
872,572

 
$
888,564

 
$
1,761,136


The Company recognized $0.2 million and $0.5 million of amortization expense for the three months ended September 29, 2018 and September 30, 2017, respectively, and $0.7 million and $1.1 million of amortization expense for the nine months ended September 29, 2018 and September 30, 2017, respectively, related to intangible assets. At September 29, 2018 and December 30, 2017, the Company's intangible assets include customer relationships, developed technology and a trade name, which had a total carrying value of $2.5 million, total accumulated amortization of $2.2 million and $1.6 million, respectively, and a total net book value of $0.2 million and $0.9 million, respectively. The intangibles have a remaining life of less than one year as of September 29, 2018.
v3.10.0.1
CONTRACT ASSETS AND CONTRACT LIABILITIES (Notes)
9 Months Ended
Sep. 29, 2018
Contract Assets and Contract Liabilities [Abstract]  
Contract Assets (Liabilities), Net [Text Block]
12.     CONTRACT ASSETS AND LIABILITIES
Net contract assets (liabilities) consisted of the following:
 
September 29, 2018
 
December 30, 2017
 
$ Change
 
% Change
Contract assets—current
$
1,935,262

 
$
704,863

 
$
1,230,399

 
175
 %
Contract assets—noncurrent
400,000

 

 
400,000

 
 %
Contract liabilities—current
(428,642
)
 
(1,181,712
)
 
753,070

 
(64
)%
Contract liabilities—noncurrent
(154,769
)
 
(374,171
)
 
219,402

 
(59
)%
Net contract assets (liabilities)
$
1,751,851

 
$
(851,020
)
 
$
2,602,871

 
(306
)%

The $2.6 million increase in the Company's net contract assets (liabilities) from December 30, 2017 to September 29, 2018 was primarily due to the adoption of Topic 606.
In the three and nine months ended September 29, 2018, the Company recognized revenue of less than $0.1 million and $0.2 million, respectively, related to our contract liabilities at December 31, 2017. In the three and nine months ended September 30, 2017, the Company recognized revenue of $0.1 million and $0.3 million, respectively, related to our contract liabilities at January 1, 2017.
The Company did not recognize impairment losses on our contract assets in the three and nine months ended September 29, 2018 and September 30, 2017.
v3.10.0.1
SEGMENTS AND GEOGRAPHICAL INFORMATION
9 Months Ended
Sep. 29, 2018
Segment Reporting [Abstract]  
SEGMENTS AND GEOGRAPHICAL INFORMATION
SEGMENTS AND DISAGGREGATION OF REVENUE
The Company’s chief operating decision maker is its Chief Executive Officer. The Company has determined it has two reportable segments: Industrial, which includes the operations that develop and manufacture its reflective display products and virtual reality systems for test and simulation products, and Kopin, which includes the operations that develop and manufacture its other products.
As noted in Note 2. Accounting Standards, effective December 31, 2017, the Company adopted Topic 606 using the modified retrospective method. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.
Segment financial results were as follows:
 
Three Months Ended
 
Nine Months Ended
Total Revenue (in thousands)
September 29, 2018
 
September 30, 2017
 
September 29, 2018
 
September 30, 2017
Kopin
$
3,629

 
$
3,744

 
$
11,033

 
$
10,409

Industrial
1,895

 
2,395

 
6,549

 
6,036

Eliminations
(398
)
 

 
(858
)
 

Total
$
5,126

 
$
6,139

 
$
16,724

 
$
16,445

 
 
 
 
 
 
 
 
 
Three Months Ended
 
Nine Months Ended
Total Intersegment Revenue (in thousands)
September 29, 2018
 
September 30, 2017
 
September 29, 2018
 
September 30, 2017
Kopin
$

 
$

 
$

 
$

Industrial
398

 

 
858

 

Total
$
398

 
$

 
$
858

 
$

 
 
 
 
 
 
 
 
 
Three Months Ended
 
Nine Months Ended
Net Loss Attributable to Kopin (in thousands)
September 29, 2018
 
September 30, 2017
 
September 29, 2018
 
September 30, 2017
Kopin
$
(9,814
)
 
$
(8,117
)
 
$
(24,650
)
 
$
(23,170
)
Industrial
23

 
(130
)
 
81

 
(268
)
Total
$
(9,791
)
 
$
(8,247
)
 
$
(24,569
)
 
$
(23,438
)
 
 
 
 
 
 
 
 
Total Assets (in thousands)
 
 
 
 
September 29, 2018
 
December 30, 2017
Kopin
 
 
 
 
$
62,573

 
$
82,707

Industrial
 
 
 
 
9,052

 
8,615

Total
 
 
 
 
$
71,625

 
$
91,322


Total long-live assets by country at September 29, 2018 and December 30, 2017 were:
Total Long-lived Assets (in thousands)
September 29, 2018
 
December 30, 2017
U.S.
$
2,103

 
$
2,456

United Kingdom
228

 
192

China
2,575

 
338

Japan
142

 
206

Korea
28

 
1,885

Total
$
5,076

 
$
5,077

We disaggregate our revenue from contracts with customers by geographic location and by display application, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.
During the three and nine months ended September 29, 2018 and September 30, 2017, the Company derived its sales from the following geographies:
 
Three Months Ended September 29, 2018
 
Kopin
 
Industrial
 
Total
(In thousands, except percentages)
Revenue
 
% of Total
 
Revenue
 
% of Total
 
Revenue
 
% of Total
United States
$
2,427

 
47
%
 
$
820

 
16
%
 
$
3,247

 
63
%
Other Americas
14

 

 
6

 

 
20

 

        Total Americas
2,441

 
48

 
826

 
16

 
3,267

 
64

Asia-Pacific
863

 
17

 
324

 
6

 
1,187

 
23

Europe
325

 
6

 
341

 
7

 
666

 
13

Other

 

 
6

 

 
6

 

       Total Revenues
$
3,629

 
71
%
 
$
1,497

 
29
%
 
$
5,126

 
100
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended September 30, 2017
 
Kopin
 
Industrial
 
Total
(In thousands, except percentages)
Revenue
 
% of Total
 
Revenue
 
% of Total
 
Revenue
 
% of Total
United States
$
2,000

 
33
%
 
$
886

 
14
%
 
$
2,886

 
47
%
Other Americas
3

 

 

 

 
3

 

        Total Americas
2,003

 
33

 
886

 
14

 
2,889

 
47

Asia-Pacific
1,200

 
20

 
168

 
3

 
1,368

 
22

Europe
541

 
9

 
1,341

 
22

 
1,882

 
31

       Total Revenues
$
3,744

 
61
%
 
$
2,395

 
39
%
 
$
6,139

 
100
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 29, 2018
 
Kopin
 
Industrial
 
Total
(In thousands, except percentages)
Revenue
 
% of Total
 
Revenue
 
% of Total
 
Revenue
 
% of Total
United States
$
7,586

 
45
%
 
$
2,814

 
17
%
 
$
10,400

 
62
%
Other Americas
43

 
1

 
29

 

 
72

 
1

        Total Americas
7,629

 
46

 
2,843

 
17

 
10,472

 
63

Asia-Pacific
2,331

 
14

 
1,484

 
9

 
3,815

 
23

Europe
1,073

 
6

 
1,336

 
8

 
2,409

 
14

Other

 

 
28

 

 
28

 

       Total Revenues
$
11,033

 
66
%
 
$
5,691

 
34
%
 
$
16,724

 
100
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2017
 
Kopin
 
Industrial
 
Total
(In thousands, except percentages)
Revenue
 
% of Total
 
Revenue
 
% of Total
 
Revenue
 
% of Total
United States
$
6,166

 
37
%
 
$
1,742

 
11
%
 
$
7,908

 
48
%
Other Americas
13

 

 
22

 

 
35

 

        Total Americas
6,179

 
37

 
1,764

 
11

 
7,943

 
48

Asia-Pacific
2,800

 
17

 
1,349

 
8

 
4,149

 
25

Europe
1,430

 
9

 
2,915

 
18

 
4,345

 
27

Other

 

 
8

 

 
8

 

       Total Revenues
$
10,409

 
63
%
 
$
6,036

 
37
%
 
$
16,445

 
100
%
During the three and nine months ended September 29, 2018 and September 30, 2017, the Company derived its sales from the following display applications:
 
Three Months Ended September 29, 2018
 
Three Months Ended September 30, 2017
(In thousands)
Kopin
 
Industrial
 
Total
 
Kopin
 
Industrial
 
Total
Military
$
582

 
$
917

 
$
1,499

 
$
913

 
$
1,872

 
$
2,785

Industrial
721

 
562

 
1,283

 
657

 
519

 
1,176

Consumer
816

 

 
816

 
1,282

 

 
1,282

R&D
1,482

 
1

 
1,483

 
550

 

 
550

Other
28

 
17

 
45

 
342

 
4

 
346

Total Revenues
$
3,629

 
$
1,497

 
$
5,126

 
$
3,744

 
$
2,395

 
$
6,139

 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 29, 2018
 
Nine Months Ended September 30, 2017
(In thousands)
Kopin